Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 732686, 6 pages
http://dx.doi.org/10.1155/2015/732686
Research Article

The Impact of Gene Polymorphisms on the Success of Anticholinergic Treatment in Children with Overactive Bladder

1Department of Urology, Gazi University School of Medicine, 06500 Ankara, Turkey
2Department of Medical Biology and Genetics, Gazi University School of Medicine, 06500 Ankara, Turkey
3Department of Urology, Osmangazi University School of Medicine, 26040 Eskisehir, Turkey

Received 9 April 2015; Revised 5 June 2015; Accepted 8 June 2015

Academic Editor: Yi-Chia Huang

Copyright © 2015 Serhat Gurocak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Franco, “Overactive bladder in children. Part 1: pathophysiology,” Journal of Urology, vol. 178, no. 3, part 1, pp. 761–768, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. M.-D. Leclair and Y. Héloury, “Non-neurogenic elimination disorders in children,” Journal of Pediatric Urology, vol. 6, no. 4, pp. 338–345, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Franco, “Overactive bladder in children. Part 2: management,” Journal of Urology, vol. 178, no. 3, part 1, pp. 769–774, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Boureux, E. Vignal, S. Faure, and P. Fort, “Evolution of the Rho family of Ras-like GTPases in eukaryotes,” Molecular Biology and Evolution, vol. 24, no. 1, pp. 203–216, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Matsushita, K. Ashikawa, K. Yonemoto et al., “Functional SNP of ARHGEF10 confers risk of atherothrombotic stroke,” Human Molecular Genetics, vol. 19, no. 6, Article ID ddp582, pp. 1137–1146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. K.-E. Anderson, “Pharmacology of lower urinary tract smooth muscles and penile erectile tissues,” Pharmacological Reviews, vol. 45, no. 3, pp. 253–308, 1993. View at Google Scholar · View at Scopus
  7. M. Nomiya and O. Yamaguchi, “A quantitative analysis of mRNA expression of α1 and β-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders,” Journal of Urology, vol. 170, no. 2, pp. 649–653, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Yamaguchi, “β3-Adrenoceptors in human detrusor muscle,” Urology, vol. 59, no. 5, pp. 25–29, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Morita, H. Iizuka, T. Iwata, and S. Kondo, “Function and distribution of β3-adrenoceptors in rat, rabbit and human urinary bladder and external urethral sphincter,” Journal of Smooth Muscle Research, vol. 36, no. 1, pp. 21–32, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. O. Yamaguchi and C. R. Chapple, “Beta3-adrenoceptors in urinary bladder,” Neurourology and Urodynamics, vol. 26, no. 6, pp. 752–756, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. C. R. Chapple, S. A. Kaplan, and D. Mitcheson, “Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder,” European Urology, vol. 63, pp. 296–305, 2013. View at Google Scholar
  12. K. Clément, C. Vaisse, B. S. J. Manning et al., “Genetic variation in the β3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity,” The New England Journal of Medicine, vol. 333, no. 6, pp. 352–354, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. E. M. J. Gillam, Z. Guo, Y.-F. Ueng et al., “Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities,” Archives of Biochemistry and Biophysics, vol. 317, no. 2, pp. 374–384, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Gellner, R. Eiselt, E. Hustert et al., “Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene,” Pharmacogenetics, vol. 11, no. 2, pp. 111–121, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. L. P. W. Witte, W. M. C. Mulder, J. J. M. C. H. de la Rosette, and M. C. Michel, “Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?” Current Opinion in Urology, vol. 19, no. 1, pp. 13–19, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. R. H. Zobrist, B. Schmid, A. Feick, D. Quan, and S. W. Sanders, “Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers,” Pharmaceutical Research, vol. 18, no. 7, pp. 1029–1034, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Akbal, Y. Genc, B. Burgu, E. Ozden, and S. Tekgul, “Dysfunctional voiding and incontinence scoring system: quantitative evaluation of incontinence symptoms in pediatric population,” Journal of Urology, vol. 173, no. 3, pp. 969–973, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Matsushita, K. Ashikawa, K. Yonemoto et al., “Functional SNP of ARHGEF10 confers risk of atherothrombotic stroke,” Human Molecular Genetics, vol. 19, no. 6, pp. 1137–1146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Kandabashi, H. Shimokawa, K. Miyata et al., “Inhibition of myosin phosphatase by upregulated Rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1β,” Circulation, vol. 101, no. 11, pp. 1319–1323, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Mukai, H. Shimokawa, T. Matoba et al., “Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension,” The FASEB Journal, vol. 15, no. 6, pp. 1062–1064, 2001. View at Google Scholar · View at Scopus
  21. M. Uehata, T. Ishizaki, H. Satoh et al., “Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension,” Nature, vol. 389, no. 6654, pp. 990–994, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Peterson, H. Laivuori, E. Kerkelä et al., “ROCK2 allelic variants are not associated with pre-eclampsia susceptibility in the Finnish population,” Molecular Human Reproduction, vol. 15, no. 7, pp. 443–449, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Buyse, K. Waldeck, C. Verpoorten, H. Björk, P. Casaer, and K.-E. Andersson, “Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism,” Journal of Urology, vol. 160, part 1, no. 3, pp. 892–896, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Goessl, T. Sauter, T. Michael, B. Bergé, M. Staehler, and K. Miller, “Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia,” Urology, vol. 55, no. 3, pp. 414–418, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Yucel, E. Akkaya, E. Guntekin et al., “Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?” Urology, vol. 65, no. 2, pp. 369–373, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Nomiya and O. Yamaguchi, “A quantitative analysis of mRNA expression of α1 and β-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders,” The Journal of Urology, vol. 170, no. 2, pp. 649–653, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Kaidoh, Y. Igawa, H. Takeda et al., “Effects of selective β2 and β3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats,” Journal of Urology, vol. 168, no. 3, pp. 1247–1252, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Takeda, Y. Yamazaki, Y. Igawa et al., “Effects of β3-adrenoceptor stimulation on prostaglandin E2-induced bladder hyperactivity and on the cardiovascular system in conscious rats,” Neurourology and Urodynamics, vol. 21, no. 6, pp. 558–565, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Arner and J. Hoffstedt, “Adrenoceptor genes in human obesity,” Journal of Internal Medicine, vol. 245, no. 6, pp. 667–672, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Honda, M. Nomiya, K. Shishido et al., “Mutation of beta3-adrenoceptor gene: a genetic marker for overactive bladder,” Neurourology and Urodynamics, vol. 25, p. 652, 2006. View at Google Scholar
  31. M. Yaïch, M. Popon, Y. Médard, and E. J. Aigrain, “In-vitro cytochrome P450 dependent metabolism of oxybutynin to N- deethyloxybutynin in humans,” Pharmacogenetics, vol. 8, no. 5, pp. 449–451, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Wang, Y. Guo, S. A. Wrighton, G. E. Cooke, and W. Sadee, “Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs,” Pharmacogenomics Journal, vol. 11, no. 4, pp. 274–286, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Muller, W. Siegmund, R. Huupponen et al., “Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 18, no. 3, pp. 265–272, 1993. View at Publisher · View at Google Scholar · View at Scopus